[Analysis of therapeutic effect of non-bioartificial liver on cholestatic liver disease in children].

The patients diagnosed with cholestatic liver disease at Beijing Children's Hospital, Capital Medical University from April 2022 to April 2024 were retrospectively collected and divided into non-biological artificial liver (NBAL) group and standard medical therapy (SMT) group according to treatment methods. The decline of liver function indexes 3, 7 and 14 days after treatment was compared until Auaust 2024. The NBAL group was divided into plasma exchange (PE) group, plasma adsorption group and combined treatment group according to the treatment mode. The decline of liver function indicators before and after different treatment modes was compared. A total of 16 patients were included. There were 8 patients in the SMT group, including 5 males and 3 females, aged (7.5±3.3) years. There were 8 patients in the NBAL group, including 2 males and 6 females, aged (6.9±4.6) years. The patients were followed up for 28 months. On the 3rd day of treatment, the decrease of total bilirubin (TBIL) [(118.8±95.3) vs (18.2±45.7) μmol/L] and direct bilirubin (DBIL) [(96.2±81.5) vs (18.2±45.7) μmol/L] in NBAL group was higher than that in SMT group; On the 7th and 14th day of treatment, the decrease of TBIL and DBIL in NBAL group was higher than that in SMT group (all P<0.05). The 8 children in the NBAL group received artificial liver treatment for 23 times, including 8 in the PE group, 9 in the plasma adsorption group, and 6 in the combined treatment group. The decrease of alanine aminotransferase (ALT) in PE group was higher than that in plasma adsorption group and combined treatment group [(175.5±79.4) vs (107.9±70.5) and (60.3±87.2) U/L, respectively, both P<0.05]. The therapeutic effect of NBAL on cholestatic liver disease in children is better than that of medical treatment. The effect of plasma adsorption and combined therapy is equivalent to that of PE in reducing liver function indexes.